Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 18,85 € (+45,34%). Mediana wynosi 19,16 € (+47,73%).
| Kupuj |
9 |
| Trzymaj |
2 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Erasca places shares for $550 million at $17.50 per share
Erasca placed 31,428,572 common shares at $17.50 per share and expects gross proceeds of about $550 million. The lead managers were granted a 30-day option to purchase up to 4,714,285 additional shares at the offering price. Net proceeds are intended to finance research and development, ongoing development programs and working capital; the closing of the transaction is expected on July 15, 2026. » Więcej na de.investing.com
Erasca plans $500 million capital raise despite positive phase‑1 data
Erasca announced a guaranteed public placement of common stock totaling $500 million plus a 30‑day option for $75 million; the proceeds are intended for R&D and working capital, which triggered shareholder dilution concerns and sent the stock down about 3.1% in after‑hours trading. At the same time the company released updated phase‑1 data for ERAS‑0015: an unconfirmed overall response rate of 57% at eight weeks in patients with ductal pancreatic cancer and KRAS‑G12X mutation; recommended dose 32 mg once daily, with six of seven patients remaining on treatment. Goldman Sachs initiated coverage with an "Early‑Stage Biotech" rating and views Erasca as a leader in RAS targeting behind Revolution Medicines; ongoing litigation and a weak market backdrop heighten near‑term risks. » Więcej na de.investing.com
Erasca plans $500 million share offering to finance research
Erasca intends to issue common shares in a syndicated public offering totaling $500 million and to grant the bookrunners a 30-day option to purchase additional shares worth up to $75 million. The securities will be offered under an S-3 shelf registration; J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are leading the syndicate. Net proceeds and existing cash will be used to fund research and development, working capital and general corporate purposes. The announcement follows a strong share rally and a market capitalization of about $5.57 billion; the stock is rated overvalued in the analysis and the company remains unprofitable (EPS -$0.96). » Więcej na de.investing.com
Erasca reports positive phase 1 data for RAS inhibitor ERAS‑0015
Erasca released preliminary phase 1 results for the oral pan‑RAS inhibitor ERAS‑0015: in the AURORAS‑1 study, seven PDAC patients with KRAS G12X showed an unconfirmed overall response rate of 57% at eight weeks. The recommended dose for the expansion phase is 32 mg once daily; treatment‑related adverse events were mostly mild, with no dose‑limiting toxicities or treatment‑related discontinuations. Combination data with panitumumab showed no DLTs in the 16 mg cohort; Erasca plans phase 3 trials in PDAC and RAS‑mutant NSCLC for 2027/2028 and expects further data in H1 2027. The positive results contributed to a strong share price increase and a market capitalization of about $5.57 billion. » Więcej na de.investing.com
Erasca bets on drug candidate ERAS‑0015 despite earlier setbacks
Erasca is a development-only precision oncology company without any revenue base, whose future depends on the success of its flagship candidate ERAS‑0015. After a death in an early trial and a patent dispute, the stock suffered significant losses in spring 2026, but market value still stood at over USD 5.7 billion in July 2026. The business model remains based on venture capital and partnerships, while the clinical progress of ERAS‑0015 will determine further growth. » Więcej na finanzen.net
Dane finansowe spółki
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | 0 | - |
| Zysk netto | -45,32 mln | 73,73% |
| EBITDA | -44,69 mln | 75,65% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 4,45 mld € |
Liczba akcji | 350,96 mln |
Maksimum/minimum z 52 tygodni | 22,15 € - 2,51 € |
| Dywidendy | Nie |
Beta | 0,65 |
C/Z (PE Ratio) | -14,03 |
PEG (PEG Ratio) | 0,13 |
C/WK (PB Ratio) | 5,22 |
C/S (PS Ratio) | 0,00 |
Profil spółki
Erasca, Inc., spółka biofarmaceutyczna na etapie badań klinicznych, koncentruje się na odkrywaniu, rozwoju i komercjalizacji terapii dla pacjentów z nowotworami napędzanymi przez szlak RAS/MAPK. Do wiodących kandydatów firmy należą ERAS-007, doustny inhibitor ERK1/2 stosowany w leczeniu raka płuca niedrobnokomórkowego, raka jelita grubego i ostrej białaczki szpikowej, oraz ERAS-601, doustny inhibitor SHP2 przeznaczony dla pacjentów z zaawansowanymi lub przerzutowymi guzami litymi. Firma rozwija również ERAS-801, inhibitor EGFR przenikający do ośrodkowego układu nerwowego, do leczenia pacjentów z nawrotowym glejakiem wielopostaciowym. Spółka została założona w 2018 roku i ma siedzibę w San Diego w Kalifornii.
| Nazwa | ERASCA INC. DL -,0001 Aktie |
| CEO | Jonathan E. Lim |
| Siedziba | San Diego,
ca Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 16.07.2021 |
| Pracownicy | 103 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | ERAS |